Combination therapy for advanced ampullary cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs for a rare type of cancer at the ampulla of Vater, where the bile duct and pancreatic duct meet. The goal is to see if this combination can shrink tumors or slow their growth in people whose cancer cannot be removed with surgery or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ampullary cancer that has spread to other parts of the body or has come back and cannot be removed with surgery.
- You have not had chemotherapy or other systemic treatment for advanced ampullary cancer (unless you had chemo after surgery and it came back more than 6 months later).
- You are physically active (can do light work or live independently) and have a life expectancy of at least 12 weeks.
- You have at least one tumor that can be measured on scans.
- Your blood counts and kidney, liver, and heart functions are within required limits.
- You agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with bile duct cancer that cannot be removed by surgery or has spread. The treatment combines a targeted drug (surufatinib) with immunotherapy and chemotherapy to try to shrink tumors and improve outcomes.
This study tests a combination of two drugs (surufatinib and toripalimab) plus a chemo infusion directly into the liver (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two medications (envafolimab and surufatinib) plus a procedure that uses heat to destroy cancer cells inside the bile ducts. It is for people with bile duct or gallbladder cancer that cannot be removed surgically and who are not candidates for or do not want chemotherapy.
This trial tests a new combination of drugs (including an oral targeted therapy and an immunotherapy) given before surgery for pancreatic cancer that is hard to remove or has high-risk features. The goal is to shrink the tumor to make surgery more likely to be successful.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
Hear when a new Ampullary Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.